BENGALURU: In a landmark development for global public health, researchers from the Indian Institute of Science (IISc) in Bengaluru, in collaboration with the Technical University of Denmark (DTU), have successfully engineered a lab-produced recombinant antivenom to combat lethal snakebites. The new treatment provides broad-spectrum protection against the venom of prominent Indian cobra species, including the spectacled cobra, monocled cobra, and both variants of the Indian king cobra.
Snakebites remain a severe health crisis, claiming the lives of approximately 50,000 people in India annually. Traditional antivenoms, which have been relied upon for over a century, involve injecting snake venom into animals like horses or sheep and harvesting the resulting antibodies. However, this conventional production method comes with significant drawbacks, including batch-to-batch variability, low therapeutic concentrations, severe allergic side effects, and heavy reliance on animal welfare and continuous animal immunisation.
To bypass these limitations, the research team turned to modern biotechnology. They utilised camelid antibodies—specifically tiny antibody fragments known as "nanobodies," which were originally derived from camelids like alpacas and llamas. By repurposing and engineering nanobodies previously studied against African snake toxins, the scientists successfully identified a cocktail of five distinct nanobodies that specifically target and neutralize shared, medically relevant toxin families found in Indian cobras.
Pre-clinical evaluations yielded extraordinary results. When tested on mice injected with lethal doses of cobra venom, the antibody cocktail successfully protected the animals from paralysis and death. Remarkably, the treatment remained effective even when administered 30 minutes post-injection, successfully reversing severe neurotoxic symptoms and returning paralyzed mice to a completely healthy state.
"The novel nanobody cocktail efficiently targets both spectacled and monocellate cobras of India, as well as both species of the king cobra," noted Kartik Sunagar, lead researcher and associate professor at the Centre for Ecological Sciences, IISc. He added that the breakthrough demonstrates how precise, small-scale antibody engineering can reduce the high costs and safety concerns associated with traditional massive antibody doses.
Andreas Hougaard Laustsen and Anne Ljungars from the Technical University of Denmark emphasized that the project serves as a crucial blueprint. By focusing on shared toxin families rather than tailoring individual antivenoms for every single snake species, science moves closer to creating regionally adaptable, continent-wide biologics.
While the current formulation does not protect against other venomous snakes like kraits or vipers, the flexible framework of recombinant technology allows researchers to easily integrate additional antibody components. Moving forward, the team aims to secure funding and support for human clinical trials, bringing this next-generation, animal-free therapy closer to the patients who need it most.
